Clinical Trials
7 trialsNCT05457829 2026-05-18
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Sun Yat-sen University
Phase 2 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06816771 2025-02-10
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06684327 2024-12-20
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Fudan University
Phase 2 Recruiting